| Literature DB >> 15363979 |
Valeria Camarda1, Wei Song, Erika Marzola, Martina Spagnol, Remo Guerrini, Severo Salvadori, Domenico Regoli, Jonathan P Thompson, David J Rowbotham, David J Behm, Stephen A Douglas, Girolamo Calo', David G Lambert.
Abstract
Urotensin-II is the natural ligand of the UT receptor. This novel system is involved in the regulation of cardiovascular functions. Recently, a urotensin-II analog ([Pen5,DTrp7,Orn8]urotensin-II(4-11)) named urantide, has been proposed as a selective and potent UT receptor antagonist. In order to pharmacologically characterize this new compound, urantide was tested on the native UT receptors of the rat aorta and on the human recombinant receptors expressed in CHO cells (CHO(hUT)). Indeed, urantide behaves as a competitive, potent (pA2 8.24), and pure antagonist in the rat aorta bioassay, while as an agonist (pEC50 8.11) in a calcium mobilization assay performed in CHO(hUT) cells. Urantide should be considered a low efficacy partial agonist.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15363979 DOI： 10.1016/j.ejphar.2004.07.089
Source DB: PubMed Journal: Eur J Pharmacol ISSN： 0014-2999 Impact factor: 4.432